drugset / Trial / NCT01157715
A Randomized, Double-masked, Multicenter, Controlled Study of Intravitreal KH902 in Patients With Neovascular AMD
Phase 2
Completed
122 enrolled
Chengdu Kanghong Biotech Co., Ltd.
Beijing DMS Pharma Ltd. · collabThe Digital Angiography Reading Center (DARC) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is designed to access the safety and efficacy of multiple injections of KH902 at variable dosing regimens in patients with CNV due to neovascular AMD.
Timeline
- Start
- 2010-05
- Primary completion
- 2012-01
- Completion
- 2012-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Conbercept | Protein / enzyme biologic | 0.5 mg | Intravitreal |
| Subject | Conbercept | Protein / enzyme biologic | 2 mg | Intravitreal |